{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:30:20Z","timestamp":1790314220365,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ijid.2025.108201","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T09:49:17Z","timestamp":1762768157000},"page":"108201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Beyond minimum inhibitory concentrations: Integrating molecular resistance testing for equitable management of vaginal candidiasis"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9719-3934","authenticated-orcid":false,"given":"Bwambale","family":"Jonani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2025.108201_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(18)30103-8","article-title":"Global burden of recurrent vulvovaginal candidiasis: a systematic review","volume":"18","author":"Denning","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2025.108201_bib0002","doi-asserted-by":"crossref","first-page":"100996","DOI":"10.1016\/j.lanmic.2024.100996","article-title":"Epidemiology and drug resistance among Candida pathogens in Africa: Candida auris could now be leading the pack","volume":"6","author":"Ibe","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ijid.2025.108201_bib0003","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1128\/AAC.45.10.2676-2684.2001","article-title":"Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients","volume":"45","author":"Perea","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2025.108201_bib0004","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1128\/AAC.00926-08","article-title":"Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance","volume":"53","author":"Tsao","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2025.108201_bib0005","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1128\/EC.3.6.1639-1652.2004","article-title":"TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2","volume":"3","author":"Coste","year":"2004","journal-title":"Eukaryot Cell"},{"key":"10.1016\/j.ijid.2025.108201_bib0006","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1128\/AAC.50.4.1148-1155.2006","article-title":"Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility","volume":"50","author":"Niimi","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2025.108201_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0030164","article-title":"The transcription factor Mrr1p controls expression of the MDR1 Efflux pump and mediates multidrug resistance in Candida albicans","volume":"3","author":"Morschh\u00e4user","year":"2007","journal-title":"PLOS Pathog"},{"key":"10.1016\/j.ijid.2025.108201_bib0008","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1128\/AAC.03921-14","article-title":"Identification of genomic binding sites for Candida glabrata Pdr1 transcription factor in wild-type and \u03c10 cells","volume":"58","author":"Paul","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2025.108201_bib0009","first-page":"1217","article-title":"Research of Mrr1, Cap1 and MDR1 in Candida albicans resistant to azole medications","volume":"15","author":"Feng","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.ijid.2025.108201_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210397","article-title":"Analysis of antifungal resistance genes in Candida albicans and Candida glabrata using next generation sequencing","volume":"14","author":"Spettel","year":"2019","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ijid.2025.108201_bib0011","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00365-20","article-title":"Mutations in TAC1B: a novel genetic determinant of clinical fluconazole resistance in Candida auris","volume":"11","author":"Rybak","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.ijid.2025.108201_bib0012","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3390\/antibiotics10101217","article-title":"Two sequential clinical isolates of Candida glabrata with multidrug-resistance to posaconazole and echinocandins","volume":"10","author":"Wang","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijid.2025.108201_bib0013","first-page":"126","article-title":"Epidemiology, clinical features and antifungal resistance profile of Candida auris in Africa: systematic review","volume":"12","author":"Yerbanga","year":"2024","journal-title":"J Biosci Med"},{"key":"10.1016\/j.ijid.2025.108201_bib0014","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00300-25","article-title":"Mutations in TAC1B drive increased CDR1 and MDR1 expression and azole resistance in Candida auris","volume":"69","author":"Barker","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2025.108201_bib0015","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/1567-1364.12042","article-title":"Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans","volume":"13","author":"Xiang","year":"2013","journal-title":"FEMS Yeast Res"},{"key":"10.1016\/j.ijid.2025.108201_bib0016","article-title":"Upc2-mediated mechanisms of azole resistance in Candida auris","volume":"12","author":"Li","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijid.2025.108201_bib0017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/jof11010024","article-title":"Azole resistance and ERG11 mutation in clinical isolates of Candida tropicalis","volume":"11","author":"Siqueira","year":"2025","journal-title":"J Fungi"},{"key":"10.1016\/j.ijid.2025.108201_bib0018","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12879-020-4856-8","article-title":"Molecular mechanism of azoles resistant Candida albicans in a patient with chronic mucocutaneous candidiasis","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2025.108201_bib0019","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1186\/s12879-024-10143-3","article-title":"Review of the novel antifungal drug olorofim (F901318)","volume":"24","author":"Vanbiervliet","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2025.108201_bib0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/cid\/ciw649","article-title":"The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis","volume":"64","author":"Timbrook","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225004230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225004230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:32:31Z","timestamp":1766406751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225004230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":20,"alternative-id":["S1201971225004230"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108201","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond minimum inhibitory concentrations: Integrating molecular resistance testing for equitable management of vaginal candidiasis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108201"}}